Advertisement

Some 18 years after MIT professor Robert Langer first envisioned using an implantable reservoir as a drug delivery device, one of his companies, MicroCHIPS Inc. of Bedford, announced today that it is initiating a clinical study of a device that delivers a peptide over the course of months in women with osteoporosis.

The study, now being conducted in Denmark, will focus on controlled delivery of a parathyroid hormone, (PTH (1-34), from a programmable, multi-reservoir implanted system over the course of months without need for daily injections. The goal is to increase bone density in women suffering from severe osteoporosis.

SOURCE

Advertisement
Advertisement